戴维医疗(300314) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥140,779,306.15, representing a 13.98% increase compared to the same period last year[5] - Net profit attributable to shareholders reached ¥40,081,226.28, a significant increase of 19,550.73% year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥36,345,815.85, up 1,240.33% from the previous year[5] - The basic earnings per share (EPS) was ¥0.1392, reflecting a 19,785.71% increase compared to the same period last year[5] - Total operating revenue for the period reached ¥349,787,104.41, an increase of 7.5% compared to ¥325,808,561.28 in the previous period[18] - Net profit for the period was ¥75,997,999.34, representing a growth of 12.4% compared to ¥67,419,638.85 in the previous period[20] - Basic and diluted earnings per share increased to ¥0.2639 from ¥0.2341, marking a rise of 12.4%[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,206,557,240.46, an increase of 4.38% from the end of the previous year[5] - The company’s total non-current assets are reported at ¥316,784,696.46, an increase from ¥303,371,053.47[16] - Total current assets are reported at ¥889,772,544.00, compared to ¥852,515,793.23 at the start of the year, indicating growth[16] - The total liabilities increased to ¥168,832,557.97 from ¥165,360,163.55, reflecting a rise of 1.5%[19] - The company has a long-term equity investment valued at ¥50,067,556.21, down from ¥69,365,459.20[16] Cash Flow - Cash flow from operating activities for the year-to-date was ¥25,138,368.32, a substantial increase of 187.28%[10] - The net cash flow from operating activities for Q3 2022 was ¥25,138,368.32, a significant improvement compared to a net outflow of ¥28,803,236.80 in Q3 2021[23] - Cash generated from operating activities was ¥362,009,675.13, compared to ¥324,679,627.94 in the previous period, indicating a strong cash flow performance[22] - The total cash inflow from operating activities was ¥383,049,923.84, compared to ¥332,978,786.18 in Q3 2021, reflecting an increase of approximately 15%[23] - The company reported a net cash flow from investment activities of ¥84,254,695.53, which is a 21.80% increase year-on-year[10] - The total cash inflow from investment activities reached ¥1,199,731,847.00, up from ¥1,119,469,407.50 in the same period last year, indicating a growth of approximately 7.5%[23] Shareholder Information - The company’s total equity attributable to shareholders was ¥1,037,724,682.49, reflecting a 4.76% increase from the end of the previous year[5] - The total number of common shareholders at the end of the reporting period is 21,150[12] - The top three shareholders hold significant stakes: Chen Zaihong at 24.69%, Chen Yunqin at 21.12%, and Chen Zaiwei at 20.25%[12] - The total number of restricted shares at the end of the period is 98,645,952, with no new restrictions added during the period[13] Operational Efficiency - Operating costs decreased to ¥255,901,785.46 from ¥261,941,929.92, reflecting a reduction of 2.3%[18] - Gross profit margin improved, with gross profit amounting to ¥93,885,318.95, up from ¥63,866,631.36, indicating a significant increase in profitability[19] - The company experienced a 238.68% increase in prepayments, totaling ¥21,606,253.72, primarily due to increased material and testing fees[9] - The company reported a cash inflow from investment income of ¥9,718,602.75, slightly up from ¥9,297,907.50 in the same quarter last year[23] - Research and development expenses were ¥26,677,228.28, slightly down from ¥27,858,075.00, showing a focus on cost management in R&D[19] Foreign Exchange and Financial Management - The company experienced a positive impact from foreign exchange fluctuations amounting to ¥17,579,215.01, contrasting with a negative impact of ¥741,524.34 in Q3 2021[23] - The company’s financial expenses decreased significantly by 1,437.67% to -¥23,624,759.40, mainly due to increased exchange gains[9] - Accounts payable decreased to ¥63,290,414.37 from ¥83,933,000.98, reflecting improved cash flow management[16] Future Outlook - The company is focusing on market expansion and new product development to drive future growth[19] - The cash outflow for purchasing fixed assets and intangible assets was ¥22,977,151.47, compared to ¥3,793,525.53 in Q3 2021, indicating a significant increase in capital expenditure[23]